Jake N Lichterman

5PUBLICATIONS
25CO-AUTHORS
Innate immunityMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 27, 2026
A microbiota-derived bile acid overcomes antibiotic-induced hyporesponsiveness to immune checkpoint therapy by enhancing CD8 + T cell antitumor immunity.

|Nov 24, 2025
Timing of immune checkpoint blockade shapes anti-tumor immunity via a clock-dependent chemokine axis.

Jake N Lichterman, Tarun Srinivasan, Ruheng Wang

|Nov 10, 2023
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.

Albert Jang, Jake N Lichterman, Jeffrey Y Zhong

|Mar 03, 2023
Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity.

Yongbin Choi, Jake N Lichterman, Laura A Coughlin

|Jun 02, 2021
Mast Cells: A New Frontier for Cancer Immunotherapy.

Jake N Lichterman, Sangeetha M Reddy

Pageof 1

Frequent Collaborators

3 joint publications

Andrew Y Koh

2 joint publications

Nicole Poulides

2 joint publications

Shuheng Gan

2 joint publications

Xiaowei Zhan